LATEST NEWS

Latest Quarterly Conference Call

Piper Jaffray Conference Call

Wall Street Analyzer Interview

STOCK INFORMATION

TapImmune Inc.

NSDQ: TPIV

Volume

Day's Range

$

()

Change

52 Week Range

COMPANY OVERVIEW

TapImmune is developing immunotherapies for a variety of cancers that are designed to target both tumors and metastatic disease. The company’s next-generation technology is designed to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). The company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells.

LATEST FINANCIAL RESULTS

Q3 2017

Quarterly Results, Ended September 30, 2017      

annualReport-10-k

LATEST 10-K

IR CONTACT DETAILS

TapImmune

5 West Forsyth St. Suite 200
Jacksonville, FL 32202
T: (904) 862-6490
investor.relations@tapimmune.com